Open access agreements, also known as transformative agreements or read-and-publish deals, have grown in popularity and scale over the past decade, and many publishers view them as a rapid and sustainable way to make their journals open access. The agreements have become an increasingly popular choice among academic institutions, but could these deals be a valid option for pharma researchers too?
Our Members and Supporters attempted to answer this question at our recent roundtable meeting, with the help of representatives from a number of both large and small publishing companies.
The roundtable sparked many insightful and thought-provoking discussions about topics including:
- the need for a ‘reuse’ component in industry open access agreements to replace reprint and figure permission fees
- the challenges of monitoring open access publishing and journal usage statistics within pharma companies
- whether open access agreements influence author journal choice.
Read the full report of the meeting on our website or on our figshare page.
Related posts
Guest posts
Sorry, we couldn't find any posts.